The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.

"If you're not using an intravascular imaging modality, the PCI is not optimal," explained Haroon Faraz, MD, from Hackensack University Medical Center. Faraz is hopeful new and improved technologies will help these modalities become more popular among interventional cardiologists.

AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities.

Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.

PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.

PFA has emerged as the preferred ablation strategy for many electrophysiologists, but some questions do remain about its long-term impact. HRS is developing this new registry to be as user-friendly for clinicians as possible.

One of the event's primary takeaways was that interventional cardiology does still attract a healthy number of trainees. However, SCAI sees several ways the specialty can improve to be even more appealing in the future. 

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.” 

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

According to a new study of nearly 7,000 patients, type 1 and type 2 diabetes are both linked to significantly shorter life expectancies. The risk of sudden cardiac death appears to be highest for younger patients.

Medical misdiagnoses account for almost 800,000 deaths and other serious harms every year. Meanwhile healthcare AI is roundly celebrated for its diagnostic prowess. Can’t it help cut out a couple hundred thousand of those horrible mistakes?

The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.